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Abstract: Cefepime is an antibiotic with a broad spectrum of antimicrobial activity. However, this antibiotic
has several side effects and a high degradation rate. For this reason, the preparation and characterization
of new liposomes that are able to encapsulate this antibiotic seem to be an important research line in the
pharmaceutical industry. Anionic and cationic liposomes were prepared and characterized. All cationic
structures contained the same cationic surfactant, N,N,N-triethyl-N-(12-naphthoxydodecyl)ammonium.
Results showed a better encapsulation-efficiency percentage (EE%) of cefepime in liposomes with
phosphatidylcholine and cholesterol than with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).
The presence of cholesterol and the quantity of egg-yolk phospholipid in the liposome increased the
encapsulation percentage. The bactericidal activity against Escherichia coli of cefepime loaded into liposomes
with phosphatidylcholine was measured. The inhibitory zone in an agar plate for free cefepime was similar
to that obtained for loaded cefepime. The growth-rate constant of E. coli culture was also measured in
working conditions. The liposome without any antibiotic exerted no influence in such a rate constant. All
obtained results suggest that PC:CH:12NBr liposomes are biocompatible nanocarriers of cefepime that can
be used in bacterial infections against Escherichia coli with high inhibitory activity.
Keywords: cefepime; liposome; bactericidal activity; zeta potential; encapsulation; surfactant.
1. Introduction
Cefepime is a β-lactam antibiotic of the fourth generation, belonging to the cephalosporin group,
which is administered by infusion or by intravenous injection. This antibiotic shows a zwitterionic
structure at the determined pH values due to the presence of a charged N-methyl-pyrrolidine substitution
at the three-cephem moiety, and a carboxyl group at the same ring (see Figure 1) [1].
The β-lactam ring of the antibiotic suffers degradation at body temperature, not being stable
for 24 h in the organism [2]. This low half-life time means that continuous infusions need to be
administered to the patient in order to maintain drug concentrations higher than the MIC throughout
dosing intervals.
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Figure 1. Cefepime structure.
The low permeability shown by the outer membrane of Gram-negative bacteria, as well as the active
efflux systems in the inner membrane generated by the pathogens to protect their intracellular functions,
are known. However, the zwitterionic character of cefepime eases passage through the protein channels
of the outer membrane, showing a broad spectrum against Gram-negative bacteria [3–5], and also good
activity versus Gram-positive micro-organisms [6]. Alone, combined, or in a rotatory treatment, cefepime
seems to be efficient against several bactericidal infections [7–10].
In spite of good activity versus different pathogens, the use of cefepime provokes side effects.
In fact, this antibiotic shows high neurological toxicity, producing confusion, myoclonia, seizures,
and nonconvulsive status epilepticus in patients with distinct pathologies (for example, brain disorders,
febril neutropenia, and severe renal dysfunction) [11–14]. The use of high concentrations of this antibiotic
provoked a large percentage of sepsis-related mortality [15]. The FDA indicated in 2012 that several
instances of nonconvulsive status epilepticus could be associated with the use of this antibiotic when
nonappropriate doses are administrated to the patient. Recently, Isitan et al. published a review about
cases of cefepime-induced neurotoxicity [16].
In order to increase the short half-life time of this antibiotic and minimize its side effects,
nanocarriers can be used to encapsulate it. In this sense, liposomes are artificial vesicles of different size
(50–500 nm) formed by concentric layers of phospholipids around an aqueous core [17]. According to
the number of formed concentric lipidic membranes, uni- or multillamellar liposomes can be prepared.
The presence of hydrophilic/hydrophobic zones in the same structure permits the use of liposomes as
vehicles to transport pharmaceutical agents with diverse lipophilicity [18].
Torres et al. [19] prepared liposomal formulations for cefepime and ceftazidine by using
phosphatidylcholine, cholesterol, and α-tocopherol (vitamin E) with mass ratios of 4:1:0.002 and
8:1:0.005, following the lipid film hydration method. Obtained encapsulation-efficiency percentages
were about 2% and 6% for cefepime and ceftazidine, respectively. Results of antibacterial activity of
both liposomal cefepime and ceftazidime against P. aeruginosa indicated that liposomal formulations
can be an effective alternative in the treatment of infections caused by these micro-organisms,
and a valid approach against the development of bacterial resistance (an added problem to the use of
high doses of antibiotics in patients).
A multidisciplinary study was done to prepare and characterize liposomes by using mixtures of
diverse biocompatible and nontoxic lipids with the goal of encapsulating cefepime. Results showed
higher encapsulation efficiency (EE%) with cationic liposomes than with the anionic ones. The addition
of cationic surfactant N,N,N-triethyl-N-(12-naphthoxy dodecyl)ammonium bromide (12NBr) increased
EE%. On the other hand, cefepime loaded into cationic liposomes showed high bacterial-inhibition
activity against E. coli. The release of the antibiotic from the liposomes was also studied. The structures
of the used lipids (DOPE, PC, CH, and 12NBr) are shown in Figure 2.
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Figure 2. Structure of lipids and cholesterol used in this work.
2. Materials and Methods
2.1. Chemicals
L-α-phosphatidylcholine (PC) from egg yolk, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE), and cholesterol (CH) were purchased from Sigma-Aldrich and used as supplied.
The N,N,N-triethyl-N-(12-naphthoxydodecyl)ammonium surfactant (12NBr) was synthesized and
characterized as reported in Reference [20]. Cefepime (see Figure 1) and chloroform (analytical grade)
were from Normon (Madrid, Spain) and Merck (Mollet del Vallès, Barcelona, Spain), respectively,
and used as received.
All solutions were prepared with distillated and deionized water obtained from a Millipore
Milli-Q system (Fisher Scientific Company, Ottawa, ON, Canada), with a conductivity value lower
than 10−6 Sm−1. The pH of the solutions was maintained constant at a value of 7.4 by using a HEPES
(4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, from Sigma-Aldrich) buffer (I = 0.01 mol dm−3).
Measurements were done at 303.0 ± 0.1K.
2.2. Liposome Preparation
Cationic and anionic liposomes were prepared by using the lipid film hydration method [20,21]
with diverse modifications depending on the used lipids. In order to prepare lipid bilayers, lipids were
first dissolved in chloroform. The lipid solution was maintained for 2 min in an ultrasound machine
(J P Selecta Ultrasons system, 200 W and 50 kHz) at room temperature (for DOPE liposomes) or 38 ◦C
(for PC liposomes). Fluidity of the lipid bilayer depends on the transition temperature [22,23] of the
lipid, that is, the temperature required to induce a change in the lipid physical state from a gel phase
(ordered state with fully extended hydrocarbon chains) to a liquid crystalline phase (a more disordered
and fluid state, in which hydrocarbon tails are randomly oriented) [24].
The organic solvent of the obtained clear lipid solution was evaporated by using a rotary
evaporator for 45 min at 30 ◦C, and obtaining the lipid bilayer, which was stored at −81 ◦C for
at least 24 hours in order to avoid degradation of the phospholipids.
After 24 h, the lipid bilayer was hydrated with 2 ml of an aqueous solution of HEPES 10 mM
(pH = 7.4) containing the desired quantity of cefepime. The hydration of the lipid bilayer was done in
two steps. First, a hydration process of 50 min in 10 cycles for DOPE (25 min in 5 cycles for PC) of
vigorous shaking, a vortex process (3 min) and an ultrasound process (2 min) were alternately carried
out. The second hydration step consisted of a vigorous vortexed process of 2 h for DOPE (1 h for
PC). The formed liposomes were multillamellar and showed high polydispersity. In order to generate
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uniform populations of unilamellar liposomes with sizes lower than 200 nm, the extrusion of the
liposome solutions was done by using a miniextruder from Avanti Polar Lipids and polycarbonate
membranes of diameters of 100 and 250 nm from Whatman. All liposome solutions were extruded
10 times.
The composition of the cationic liposomes is expressed in molar fraction, α, defined as the molar
ratio between the cationic lipid and the total lipid (see Equation (1)).
α =
n+
no + n+
, (1)
n+ and no being the molar concentration of the cationic and neutral lipid, respectively. All concentrations
refer to the total volume of solution.
The composition (mass ratio) of the different prepared liposomes is shown in Table 1.
Table 1. Liposome composition (mass ratio) and characterization parameters. Encapsulation efficiency
percentage (EE%) of cefepime into these liposomes. α represents molar ratio between the cationic lipid
and the total lipid (Errors in EE% were always lower than 10%). Pdi: polydispersity index.
Liposomes SAMPLE Mass Ratio Mol Ratio α ζ/mV Size/nm Pdi EE%
PC:CH
A 5.3:1 2.5:1 - −24 ± 1 117 ± 9 0.1 17
B 1.2:1 0.6:1 - −29 ± 1 121 ± 8 0.2 19
PC:CH: 12NBr
C 21:1:1.5 10:1:1.2 0.14 +45 ± 1 138 ± 24 0.1 27
D 32:1:3.5 15:1:2.5 0.19 +42 ± 2 121 ± 13 0.2 43
E 7.6:1:1.5 3.6:1:1 0.25 +54 ± 4 104 ± 12 0.1 3
F 16:1:3.5 7.5:1:3 0.35 +48 ± 2 111 ± 14 0.2 13
DOPE:12NBr
G 1:1.6 1:2.5 0.20 +30 ± 1 107 ± 15 0.2 6
H 1:2.8 1:4.2 0.30 +28 ± 1 114 ± 14 0.3 6
I 1:4.4 1:6.7 0.40 +31 ± 1 100 ± 15 0.2 2
J 1:15 1:23 0.70 +32 ± 4 140 ± 28 0.3 8
K 1:25 1:38 0.80 +37 ± 2 107 ± 12 0.2 7
2.3. Absorbance Measurements
Absorbance spectra were performed to check stability, and characterize and quantify the
concentration of the different cefepime solutions. Absorption spectra were run in a Cary 500 SCAN
UV-vis-NIR (Varian). Quartz cells of 10 mm path length were used. Data were collected every 1 nm,
and spectra were recorded in a wavelength range from 200 to 400 nm. Standard quartz cuvettes of
10 mm were used. Blank was performed with a HEPES 10 mM solution. Temperature was maintained
constant at 303.1 ± 0.1 K.
2.4. Zeta-Potential Measurements
Zeta-potential (ζ) experiments were carried out with a Zetasizer Nano ZS Malvern Instrument
Ltd (Malver, Worcestershire, UK). This parameter measures the electrophoretic mobility of the sample
from the velocity of the particles using a Laser Doppler velocimeter (LDV, (Malver, Worcestershire,
UK). A DTS1060 polycarbonate capillary cell was used at 303.1 ± 0.1 K.
2.5. Dynamic Light-Scattering Measurements (DLS)
The size and the polydispersity index of the different liposomes were obtained from DLS
measurements by using a Zetasizer Nano ZS Malvern Instrument Ltd (UK). Samples were illuminated
with a laser at a fixed detection arrangement of 90◦ to the center of the cell area, and fluctuations
in the intensities of the scattered light were analyzed. The obtained results were the average of
10 measurements.
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2.6. Encapsulation-Efficiency Measurements
Drug encapsulation efficiency was measured by using a dialysis method. First, 500 µl of
drug-loaded liposome was added to a Pur-A-Lyzer Midi 1000 Dialysis Kit (MWCO 1 kDa) from
Sigma-Aldrich (Rancho Dominguez, CA, USA), a dialysis tubing of a molecular weight cut-off = 12 kDa
from Sigma-Aldrich was also used and results were not different). The dialyzer was sunk into a beaker
containing 80 mL of HEPES 10 mM. An aliquot of 2 mL from the buffer deposited on the beaker was
taken each 15 min. The quantification of the loaded antibiotic was carried out by UV-vis spectroscopy
at 258 nm. The taken aliquots were replaced each time by an equal volume of buffer in order to keep
the buffer volume in the beaker constant. Dialysis was followed for a period time of 24 h at least.
The EE% was obtained by using Equations (2) and (3). Each measurement was carried out in triplicate.
EE % =
[antibiotic]m
[antibiotic]total
× 100, (2)
[antibiotic]m = [antibiotic]total − [antibiotic]buffer, (3)
[antibiotic]m, [antibiotic]buffer, and [antiobiotic]total are the drug concentration encapsulated in the
liposomes, the concentration in the buffer solution, and the total concentration added to the liposomal
solution, respectively. All concentrations refer to the total solution volume.
The used cefepime concentration in the measurements was in the range of 20–120 µg/mL.
The quantification of the loaded antibiotic was carried out by UV-vis spectroscopy at 258 nm.
In order to avoid the degradation of cefepime in our measurements, these dialysis studies were
done in darkness and at 4 ◦C.
2.7. Cefepime Release
The release of the antibiotic from the PC:CH:12NBr liposome was obtained by using the same
dialysis method utilized in the encapsulation-efficiency measurements. In this case, dialysis was
carried out at 37 ◦C. Aliquots of 2 mL were taken at a certain time interval in order to know the
concentration of cefepime releasing from the liposome. The quantification of the loaded antibiotic was
carried out by UV-vis spectroscopy at 258 nm.
2.8. In Vitro Antibacterial Activity
Antibacterial activity of cefepime-loaded liposomes was tested against Gram-negative bacteria
Escherichia coli (E. coli) using the well-diffusion method on agar and a spectroscopic method in solution.
Escherichia coli strain CECT 515 [25] was incubated in a Luria-Bertani medium [26] overnight at
37 ◦C with continuous shaking at 180 rpm. This culture reached a cell concentration of approximately
109 cells/mL, and the E. coli culture was diluted 10 times (~108 cells/mL). Then, 200 µL was spread from
this diluted culture on LB plates containing 2% agar. Each LB plate contained about 2 × 107 E. coli cells.
In a first qualitative study, antimicrobial activity was evaluated as follows: 100 µL of cefepime-free,
PC liposomes, and cefepime-loaded liposomes was uniformly added to disks of an extra-thick blot
filter paper from Bio-Rad, sufficiently separated, and put on the agar plates. The plates were incubated
at 37 ◦C for 24 h. After the incubation period, the diameters of the growth-inhibition zones were
measured. Used cefepime concentrations were 120, 70, 50, and 20 µg/mL.
Second, a quantitative study was followed to calculate the inhibition that the cefepime loaded
into the liposomes exerted on the growth of E. coli bacterial suspensions in liquid cultures. Both cell
and cefepime concentrations used in this quantitative method were the same as those used in the agar
plates (about 2× 107 of E. coli cells and 20 µg/mL of the antibiotic). Microbial growth was evaluated by
measuring the absorbance of the culture at 600 nm in a Synergy HTX Multi-Mode Microplate Reader
from Biotek with the use of 96-well plates. Absorbance measurements were done at 37 ◦C.
All measurements were repeated 3 times.
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3. Results and Discussion
Anionic and cationic liposomes were prepared and characterized. ζ is the potential in the sliding
plane of colloidal particles that is closely related to the characteristics of electric double layers in these
nanostructures. Table 1 collects zeta-potential values obtained for the prepared diverse liposomes.
As can be seen, ζ value slightly depends on the quantity of added lipid. In the case of the anionic
liposomes (PC:CH), an increase in lipid concentration does not exert any influence on the zeta-potential
value of such structures. In the case of cationic liposomes (PC:CH:12NBr), ζ value decreases with
lipid mass at constant masses of both cholesterol and cationic surfactant (samples C and E in Table 1).
The same variation was observed comparing samples D and F in Table 1. This behavior takes place due
to the slight negative charge of the used phosphatidylcholine in this work. However, no dependence
of zeta potential was observed on the α parameter (see Equation (1)).
With respect to liposomes formulated with DOPE and cationic surfactant 12NBr, no dependence
was observed with molar fraction α, either. If different cationic formulations prepared with DOPE or
PC are compared, results show higher zeta-potential values for liposomes with PC than those with
DOPE for the same α molar fractions. All these trends are difficult to explain. The different lipid
structures or packing of each lipid bilayer influences zeta-potential values.
Dynamic light scattering (DLS) evaluates the hydrodynamic radius of particles in a solution.
Size data obtained for the liposomes prepared in this work, as well as the polydispersity obtained,
are collected in Table 1. According to the results, the different liposomes had similar sizes, about 100 nm.
This is an excellent size value for a drug nanocarrier to be intravenously administrated [27]. Sizes do
not practically depend on the character of the lipid (PC or DOPE, see Figure 1), or on the presence or
absence of the antibiotic, as observed in Figure 3. However, size depends on the α parameter, that is,
on the fraction of cationic surfactant, increasing for lower α values (see Figure 4).
The polydispersity index (Pdi) determines the homogeneity grade in the size of a particle solution.
A sample is considered homogeneous when Pdi is lower than 0.3 [28]. As is shown in Table 1,
the obtained Pdi values are ≤0.3, demonstrating the homogeneity of the prepared liposomes with
respect to their sizes.
Figure 3. Intensity/size distribution of a liposome containing L-α-phosphatidylcholine (PC), cholesterol
(CH), and N,N,N-triethyl-N-(12-naphthoxy dodecyl)ammonium bromide (12NBr) (Sample C in Table 1)
in the (A) absence and (B) presence of cefepime.
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Figure 4. Dependence of liposome size on the α parameter for different liposomes. Error bars represent
standard deviation in each α value (n = 5).
The prepared liposomes were used as cefepime nanocarriers. Obtained encapsulation-efficiency
values from dialysis are shown in Table 1. Figure 5 shows an example of the absorbance variation
observed in the dialysis process.
Figure 5. Absorbance dependence on time in a dialysis process (liposome PC + CH, Sample A). Error
bars represent standard deviation in each time value (n = 5).
Higher encapsulation efficiency takes place in liposomes with PC and CH in comparison with
those containing DOPE as a lipid. It is known that cholesterol affects the mechanical properties of
lipid membranes. It increases their mechanical strength, influences membrane elasticity, and increases
packing density through the ordering and condensing effects [29–31]. In fact, the presence of this
sterol generates a less-permeable membrane. This explains why encapsulation efficiency would be
higher with liposomes in the presence of cholesterol. On the other hand, the EE% is also augmented
by increasing total lipid concentration (PC and 12NBr) with respect to CH quantity in these cationic
liposomes (see Table 1, Samples C–F).
The EE% value of cefepime does not show any relation to the liposome size (see Table 1). However,
there is an augmentation of encapsulation efficiency with zeta potential (a more positive superficial
charge seems to favor the encapsulation process), although the percentage of cholesterol could also
exert some influence.
Pharmaceutics 2019, 11, 69 8 of 12
Our results are in accordance with those obtained by other authors [19] with similar liposomes
(PC + CH + α-tocopherol, with mass ratios 8:1:0.005 and 4:1:0.0022). Torres et al. obtained an EE%
value of 2%, while a value of about 3% was obtained in this work with the same mass ratio of PC
and CH. At least initially, the presence of 12NBr (or α-tocopherol) seems to not exert any influence.
However, an increase in liposome charge due to the presence of a cationic surfactant demonstrated
an increase in EE% value. It is worth noting that an increase of both the PC and CH percentage, and the
liposome charge, augmented cefepime’s EE%. Therefore, liposome composition was optimized in
this work.
The release of cefepime from PC:CH:12NBr liposomes was also measured (see Figure 6).
The variation of EE% with time was observed and it is shown in Figure 6A. Cefepime takes about
10 hours to leave the liposome at 37 ◦C, while the liposome takes about five days to change its size and
Pdi at the same temperature (see Figure 6B).
It is known that cefepime shows high activity against many Gram-negative micro-organisms [32,33].
The bacterial activity of cefepime loaded into liposomes was tested against the E. coli bacterium through
in vitro measurements in PC:CH:12NBr liposomes. Figure 7 shows the qualitative results obtained from
agar well-diffusion assays. Significant inhibitory activity against E. coli was observed. Data for free cefepime
are similar to those obtained with liposomes loaded with cefepime, always for the same concentration of
antibiotics (see Disks 1 and 4 in Figure 7B). The liposome without antibiotic did not show any inhibitory
activity against such bacteria (see Disks 3 and 4 in Figure 7A, and Disk 2 in Figure 7B).
Figure 6. (A) Release of cefepime from liposome PC:CH:12NBr (Sample C) at 37 ◦C. (B) Size and Pdi of
liposome PC:CH:12NBr (Sample C) at different times.
Figure 7. Zones of inhibition produced by cefepime after 24 h of incubation at different antibiotic
concentrations and 37 ◦C: (A) [Cefepime]free = 120 µg/mL (1); [Cefepime]encapsulated = 120 µg/mL (2),
50 µg/mL (5), 20 µg/mL (6). Disks 3 and 4 only contain liposomes. Sample D in Table 1 was used in
this assay. (B) [Cefepime]free = 70 µg/mL (1); [Cefepime]encapsulated = 120 µg/mL (3), 70 µg/mL (4).
Disk 2 contains liposome without cefepime. Sample F in Table 1 was used in this assay.
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The zone of inhibition increased with respect to cefepime concentration (see Disks 1, 2, 5,
and 6 in Figure 7A). This zone also shows dependence on incubation time for these drug carriers
(see Figures 7 and 8). A plateau was observed in the plot of the inhibitory zone versus time.
Although inhibition zones provoked by cefepime are similar in the presence and absence of liposome,
the obtained plateau appeared a little later for the antibiotic encapsulated into liposomes than for
the free antibiotic. This is related to the release of the antibiotic from the nanocarrier. This result
suggests that PC:CH:12NBr liposomes are good drug carriers, and show good effectiveness in killing
E. coli bacteria.
Figure 8. Dependence of inhibition zone with time in the presence and absence of PC:CH:12NBr
liposomes at 37 ◦C. Error bars represent standard deviation in each time value (n = 3).
Inhibitory activity against E. coli was also studied in solution. Absorbance corresponding to
bacterial population was measured in the presence and absence of the cefepime antibiotic and/or the
PC:CH:12NBr liposome. Figure 9 shows the absorbance results measured at 600 nm at different times.
As can be seen, cefepime inhibited the growth of E. coli. The inhibition was the same for both free and
encapsulated antibiotic for cefepime concentrations equal to 2 and 5 µg/mL. The liposome exerted no
dependence on bacterial growth. The growth-rate constant of the bacteria in the absence and presence
of liposome was calculated (see Figure 10). Assuming that cellular growth follows a first-order kinetic,
the rate constant was calculated by using Equation (4):
Ln(A∞ − At) = Ln(A∞ − Ao)− kt, (4)
where Ao, A∞, and At represent the absorbance (optical density) of the bacterial culture at a wavelength
of 600 nm at different times after incubation with the antibiotic: initial time, infinite time, and at
a determined t time, respectively. k represents the growth-rate constant of the bacteria.
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Figure 9. Growth inhibition of E. coli in the absence and presence of cefepime (free and encapsulated in
PC:CH:12NBr liposomes) at different antibiotic concentrations.
Figure 10. Determination of growth-rate constant for E. coli by using Equation (4).
The growth-rate constants of E. coli in the absence and presence of the PC:CH:12NBr liposome,
obtained by using Equation (4), were 0.4075 and 0.4033 h−1, respectively. This shows that the
liposome did not inhibit the growth of E. coli, and confirms previous results obtained from agar
well-diffusion assays.
4. Conclusions
The encapsulation of the β-lactam antibiotic cefepime was investigated into diverse cationic and
anionic liposomes with phosphatidylcholine and DOPE as lipids. A new surfactant was added to the
solution to prepare cationic liposomes. Higher encapsulation efficiency was observed for the cationic
liposomes. This is an interesting result because, in general, cationic nanostructures also show good
internalization into cells. However, encapsulation was also more favorable for liposomes formed by
phosphatidylcholine and cholesterol.
In vitro bacterial-activity studies were carried out. Results showed an inhibitory activity of
cefepime-loaded liposomes against E. coli, similar to that observed for free cefepime. Liposomes free
of antibiotic did not show any inhibitory activity at the used concentration. In fact, the growth-rate
constant of E. coli obtained in the presence and absence of the liposome without antibiotic was 0.4075
and 0.4033 h−1, respectively.
The inhibition zone was measured at different times in the presence and absence of PC:CH:12NBr
liposomes. Results showed the influence of cefepime release in inhibitory activity.
The obtained results invite us to use these liposomes, and others built with different cationic
biosurfactants, in further investigations with the β-lactam antibiotic meropenem to be used for
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parenteral administration. The low solubility of this drug and its high degradation highlight the
importance of this future research.
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